NEWSROOM
Press Releases by Agendia
News
Press Releases
MINDACT in the News
News, videos, social media and more about the recently released MINDACT phase III, prospective randomized trial results The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD at the American Association for Read More
Agendia Appoints Dr. M. William Audeh to Chief Medical Officer
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, recently announced the appointment of veteran medical oncologist M. William Audeh, MD, MS to the position of Chief Read More
Agendia’s MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could change clinical Read More
MINDACT results will be presented during the AACR Annual Meeting 2016
EORTC (European Organisation for Research and Treatment of Cancer), BIG (Breast International Group), and Agendia are pleased to announce that the “Primary analysis of the EORTC 10041/ Read More
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference (MBCC) IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine Read More
Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care
Agendia is disappointed with the recent update to the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines and with the decision to move forward without key research that we feel would have a material Read More
Agendia and Partners Receive $6.8 million from European Commission to Study Targeted Therapies for Colorectal Cancer
IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and several European partners have received a $6.8 million European Commission grant to study targeted therapies for colorectal cancer (CRC). The grantees will test therapies matched Read More
